Helius Therapeutics has launched in the Australian market under the brand HTL on the third anniversary of the firm’s unveiling in New Zealand.
Describing the move as “a significant milestone” in the company’s growth, CEO Carmen Doran added: “We are very proud to see that just three years after our successful launch in New Zealand, we have been able to make our products available in Australia.”
Continue reading...
